Fostemsavir approved for use in EU for treatment of multidrug-resistant HIV

Fostemsavir is a first-in-class HIV attachment inhibitor, designed to target the first step of the HIV lifecycle. It is approved for use in patients who cannot otherwise receive a suppressive antiviral-regimen. Approval was based on data from the phase III BRIGHTE study.

Source:

PharmaTimes